Trial Profile
HDL [high density lipoprotein] modulation and endothelial function
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Niacin (Primary) ; Atorvastatin
- Indications Atherosclerosis; Coronary artery disease
- Focus Pharmacodynamics
- 14 Mar 2010 Results presented at 59th Annual Scientific Session of the American College of Cardiology.
- 02 Nov 2008 Trial end date changed from 1 Jul 2008 to 1 Aug 2008 as reported by Clinicaltrials.gov.
- 02 Nov 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.